The NoLymiT team is principal investigator of the European THERAVLINFO project.
THERAVLINFO is an advance in the biomedical translation of preclinical lymphoma knowledge and models generated in IMLINFO (EFA 281/16), in order to improve the survival and quality of life of patients with hematological cancer.
OBJECTIVE: To determine the effectiveness of new immunotherapy treatments through the creation of a NHL tumour bank associated with a 3D culture platform. The project is part of axis 1 of the POCTEFA programme: Boosting innovation and competitiveness.
More informations
![InsermSeul_Rvb__noir](https://www.crct-inserm.fr/wp-content/uploads/2022/01/InsermSeul_Rvb__noir.png)
![Logo-CNRS](https://www.crct-inserm.fr/wp-content/uploads/2021/08/Logo-CNRS.png)
![logo-ut3](https://www.crct-inserm.fr/wp-content/uploads/2023/03/logo-ut3.jpg)